Novel consequences of voltage-dependence to G-protein-coupled P2Y 1 receptors

British Journal of Pharmacology

Volumn 154, Issue 4, 2008, Pages 882-889

  Gurung, I S ^a   Martinez Pinna, J ^b   Mahaut Smith, M P ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF ALICANTE   (Spain)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Antagonist; Calcium; G protein coupled receptor; P2Y 1; Voltage dependence

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 2,20 PYRIDYLISATOGEN TOSYLATE; CALCIUM ION; FURA 2; G PROTEIN COUPLED RECEPTOR; N (2,3 DIPHENYL 1,2,4 THIADIAZOL 5(2H) YLIDENE)METHANAMINE; PURINERGIC P2Y1 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; SURAMIN;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL MEMBRANE DEPOLARIZATION; CHANNEL GATING; CONTROLLED STUDY; FLUORESCENCE; MEGAKARYOCYTE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT;

ADENOSINE DIPHOSPHATE; ALLOSTERIC REGULATION; ANIMALS; CALCIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT DYES; FURA-2; MALE; MEGAKARYOCYTES; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION;

EID: 44949213749     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.97     Document Type: Article

References (43)

1. Ben Chaim Y, Chanda B, Dascal N, Bezanilla F, Parnas I, Parnas H (2006). Movement of 'gating charge' is coupled to ligand binding in a G-protein-coupled receptor. Nature 444: 106-109.
2. 2 muscarinic G-protein-coupled receptor is voltage-sensitive. J Biol Chem 278: 22482-22491.
3. 2+ signaling by the membrane potential. J Neurosci 26: 9983-9995.
4. Bolton TB, Zholos AV (2003). Potential synergy: voltage-driven steps in receptor-G protein coupling and beyond. Sci STKE 2003: pe52.
5. 6-methyl 2′-deoxyadenosine 3′,5′- bisphosphate. Br J Pharmacol 124: 1-3.
6. 1 receptor. Mol Pharmacol 50: 1323-1329.
7. Boyer JL, Zohn IE, Jacobson KA, Harden TK (1994). Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol 113: 614-620.
8. Burnstock G (2004). Cotransmission. Curr Opin Pharmacol 4: 47-52.
9. Burnstock G, Knight GE (2004). Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240: 31-304.
10. 1 receptors. J Med Chem 41: 183-190.
11. Christopoulos A, Kenakin T (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374.
12. 1 receptor antagonists. FEBS Lett 536: 145-150.
13. Colquhoun D (1998). Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125: 924-947.
14. Denk W, Yuste R, Svoboda K, Tank DW (1996). Imaging calcium dynamics in dendritic spines. Curr Opin Neurobiol 6: 372-378.
15. Fawzi AB, Macdonald D, Benbow LL, Smith-Torhan A, Zhang H, Weig BC et al. (2001). SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol Pharmacol 59: 30-37.
16. 2+ transients in guineapig coronary myocytes. J Physiol 470: 35-44.
17. Gao ZG, Gross AS, Jacobson KA (2004a). Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors. Life Sci 74: 3173-3180.
18. 1 receptor signaling without affecting nucleotide binding. Biochem Pharmacol 68: 231-237.
19. 2T-purinoceptors on human blood platelets. Br J Pharmacol 108: 728-733.
20. 1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol 53: 727-733.
21. Ilien B, Franchet C, Bernard P, Morisset S, Weill CO, Bourguignon JJ et al. (2003). Fluorescence resonance energy transfer to probe human M1 muscarinic receptor structure and drug binding properties. J Neurochem 85: 768-778.
22. Itoh T, Seki N, Suzuki S, Ito S, Kajikuri J, Kuriyama H (1992). Membrane hyperpolarization inhibits agonist-induced synthesis of inositol 1,4,5-trisphosphate in rabbit mesenteric artery. J Physiol 451: 307-328.
23. Jin J, Daniel JL, Kunapuli SP (1998). Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 273: 2030-2034.
24. 2+ release (CICR) in pancreatic beta cells. J Physiol 566: 173-188.
25. 1 purinoceptor. Br J Pharmacol 117: 1111-1118.
26. Lohse MJ, Vilardaga JP, Bunemann M (2003). Direct optical recording of intrinsic efficacy at a G protein-coupled receptor. Life Sci 74: 397-404.
27. 1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 131: 108-114.
28. 2+ release in a non-excitable cell, the rat megakaryocyte. J Physiol 515: 385-390.
29. q-coupled receptors. J Biol Chem 280: 1490-1498.
30. 2+ mobilisation in the rat megakaryocyte. J Physiol 555: 61-70.
31. 2+ oscillations in rat megakaryocytes. J Physiol 524: 437-446.
32. 3 receptors. J Physiol 533: 175-183.
33. 1 receptor. Mol Pharmacol 54: 1118-1123.
34. Pierce KL, Premont RT, Lefkowitz RJ (2002). Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3: 639-650.
35. 2+ influx. Mol Pharmacol 67: 1705-1713.
36. Ralevic V, Burnstock G (1998). Receptors for purines and pyrimidines. Pharmacol Rev 50: 413-492.
37. Spedding M, Menton K, Markham A, Weetman DF (2000). Antagonists and the purinergic nerve hypothesis: 2,2′-pyridylisatogen tosylate (PIT), an allosteric modulator of P2Y receptors. A retrospective on a quarter century of progress. J Auton Nerv Syst 81: 225-227.
38. Stanfield P (2006). Voltage sparks a GPCR. Nat Cell Biol 8: 1323-1325.
39. Sullivan JM, Shukla P (1999). Time-resolved rhodopsin activation currents in a unicellular expression system. Biophys J 77: 1333-1357.
40. 2+ waves in the non-excitable rat megakaryocyte. J Physiol 537: 371-378.
41. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH (1993). Recent research on the biological activity of suramin. Pharmacol Rev 45: 177-203.
42. 1 receptor with a high affinity radiolabeled antagonist. Mol Pharmacol 62: 1249-1257.
43. 1 receptor. Mol Pharmacol 65: 426-436.